Cello Health (LON:CLL) PT Raised to GBX 160

Cello Health (LON:CLL) had its price objective lifted by FinnCap from GBX 145 ($1.89) to GBX 160 ($2.09) in a research report report published on Wednesday, ThisIsMoney.Co.Uk reports. FinnCap currently has a corporate rating on the stock.

Shares of LON:CLL opened at GBX 127 ($1.66) on Wednesday. The firm has a market cap of $134.73 million and a P/E ratio of 20.82. The company has a quick ratio of 1.23, a current ratio of 1.28 and a debt-to-equity ratio of 4.70. Cello Health has a 12-month low of GBX 95 ($1.24) and a 12-month high of GBX 140.07 ($1.83). The business has a fifty day simple moving average of GBX 125.01 and a 200 day simple moving average of GBX 124.63.

In related news, insider Mark Bentley sold 129,800 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of GBX 127 ($1.66), for a total transaction of £164,846 ($215,400.50).

Cello Health Company Profile

Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.

Recommended Story: Understanding Average Daily Trade Volume

Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with MarketBeat.com's FREE daily email newsletter.